Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(1):16-18,58
DOI: 10.5428/pcar20190105
Preparation of oridonin nanoparticles and pharmacokinetics study in rats
1. ZHUANG Qiannan(Teaching and Research Section of Pharmaceutics,School of Pharmacy,Taishan Medical College,Shandong Taian 271016,China ken521540@gmail.com)
2. HAN Te(Teaching and Research Section of Pharmaceutics,School of Pharmacy,Taishan Medical College,Shandong Taian 271016,China )
3. WU Chaonan(Teaching and Research Section of Pharmaceutics,School of Pharmacy,Taishan Medical College,Shandong Taian 271016,China )
4. WANG Xiaodan(Teaching and Research Section of Pharmaceutics,School of Pharmacy,Taishan Medical College,Shandong Taian 271016,China )
5. HAO Jifu(Teaching and Research Section of Pharmaceutics,School of Pharmacy,Taishan Medical College,Shandong Taian 271016,China haojifu@163.com)
ABSTRACT  Objective: To prepare oridonin nanoparticles and evaluate their pharmacokinetics in rats.Methods:The oridonin poly(lactic-co-glycolic acid) (PLGA) nanoparticles were prepared by emulsion sonication and solvent evaporation method with PLGA as encapsulation materials.Their physicochemical properties were identified through determination of particle size and polydispersity index (PDI),transmission electronic microscopy(TEM) observation of the appearance form,analysis of entrapment efficiency and drug loading.The oridonin PLGA nanoparticles were administered intravenously through caudal vein in rats.Then blood concentrations of oridonin were determined by HPLC method,and the pharmacokinetics were analyzed by DAS software.Results:The particle size of the prepared nanoparticles on the average was about 180 nm,the entrapment efficiency was (87.7±7.7)% and drug loading was (7.5±0.8)% with an outward spherical appearance.The compartment model was attributed to two-compartment model after single intravenous injection of oridonin PLGA nanoparticles.The main pharmacokinetic parameters were as follows: half life of distribution phase(t1/2α) was 2.115 h,half life of elimination phase(t1/2β) was 69.315 h,the area under the curve (AUC) was 42.463 mg·h·L-1,clearance (CLwas 0.094 L·h-1·kg-1,apparent volume of distribution(V) was 0.4 L/kg.Conclusion: The preparation technology of oridonin PLGA nanoparticles is simple and feasible, with a higher entrapment efficiency.The bioavailability of oridonin couldbe improved when oridonin was fabricated into PLGA nanoparticles.
Welcome to PCAR! You are the number 52 reader of this article!
Please cite this article as:
ZHUANG Qiannan,HAN Te,WU Chaonan,WANG Xiaodan,HAO Jifu,. Preparation of oridonin nanoparticles and pharmacokinetics study in rats[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 16-18,58.
References:
1. XU Maolin,XU Yani,YE Lin,et al.Advances in oridonin targeted drug delivery system[J] Chin J Mod Appl Pharm,2014,31(8):1031-1036.In Chinese with English abstract.
2. QI Qi,ZHANG Pei,LI Qixiang,et al.Effect of oridonin on apoptosis and intracellular reactive oxygen species level in triple-negative breast cancer MDA-MB-231 cells[J].Chin J Chin Mater Med,2017,42(12):2361-2365.In Chinese with English abstract.
3. Rathor S,Bhatt D C,Aamir S,et al.A comprehensive review on role of nanoparticles in therapeutic delivery of medicine[J].Pharm Nanotechnol,2017,5(4):263-275.
4. Bala I,Hariharan S,Kumar M N.PLGA nanoparticles in drug delivery: the state of the art[J].Crit Rev Ther Drug Carrier Syst,2004,21(5):387-422.
5. Choi J S,Cao J,Naeem M,et al.Size-controlled biodegradable nanoparticles: preparation and size-dependent cellular uptake and tumor cell growth inhibition[J].Colloids Surf B Biointerfaces,2014,122:545-551.
6. Acharya S,Sahoo S K.PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect[J].Adv Drug Deliv Rev,2011,63(3):170-183.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口